How Does the FDA Evaluate AI Software That Continues to Learn After Approval?

A Regulatory Framework Built for Static Products, Facing a New Challenge

Traditional medical device regulation was generally developed around the assumption that a device, once authorized, functions essentially the same way it did during the review process. This assumption works well for most conventional medical devices, but it creates a genuine mismatch for some AI-based medical software, which may be designed to update over time, incorporate new data, or in some cases continue learning and adapting its behavior after its initial deployment. Regulating a product that might meaningfully change after it’s already on the market raises questions that don’t arise in the same way for a traditional, unchanging device: how much change is acceptable without additional review, and how can the agency ensure a device remains safe and effective as it evolves.

This is a genuinely distinct regulatory challenge, and the FDA has been actively working to develop approaches specifically suited to it, rather than simply applying the traditional static-device framework unchanged.

Developing Frameworks for Anticipated Change

One approach the FDA has explored involves allowing manufacturers to pre-specify, as part of their initial submission, the types of future modifications they anticipate a device might undergo, along with a plan for how those changes would be controlled and validated. The idea behind this kind of framework is that certain anticipated, well-characterized types of updates could potentially be implemented without requiring an entirely new full review each time, provided they fall within what was already reviewed and approved as part of the device’s overall change management plan. This reflects an attempt to balance enabling beneficial, iterative improvement of AI-based tools with maintaining appropriate regulatory oversight and safety assurance.

More significant or unanticipated changes to a device’s function generally still require some additional form of regulatory review beyond what was covered by this kind of pre-specified plan, since substantial changes could meaningfully affect a device’s safety or effectiveness profile in ways not covered by the original evaluation.

An Ongoing, Actively Developing Area of Policy

It’s important to understand that this is an actively evolving area of FDA regulatory policy rather than a long-settled, static framework. As the agency gains more experience with AI-based medical devices in real-world use, and as the underlying technology continues to develop, it’s reasonable to expect continued refinement of how adaptive AI software is regulated. Anyone seeking precise, current details on this topic should consult the FDA’s own current, authoritative guidance, since specifics in this area are more likely to change than more established, longstanding aspects of medical device regulation.

Bottom Line

The FDA has been developing specific regulatory approaches for AI-based medical software that may change or continue learning after initial authorization, including frameworks for pre-specifying anticipated future modifications, reflecting an actively evolving effort to regulate technology that behaves differently from traditional, static medical devices.

Go deeper

• What role does AI play in health insurance claims processing?
• Can AI approve or deny an insurance claim without human involvement?